Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Autism Dev Disord ; 49(2): 527-541, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30143950

ABSTRACT

This study examined the treatment efficacy of PEERS® (Program for the Education and Enrichment of Relational Skills) among Chinese adolescents with autism spectrum disorder (ASD) in Hong Kong. The original PEERS® manual was translated into Chinese, and cultural adjustments were made according to a survey among 209 local adolescents in the general population. 72 high-functioning adolescents with ASD were randomly assigned to a treatment or waitlist control group. The 14-week parent-assisted training significantly improved social skills knowledge and social functioning, and also reduced autistic mannerisms. Treatment outcomes were maintained for 3 months after training and replicated in the control group after delayed treatment. The present study represents one of the few randomized controlled trials on PEERS® conducted outside North America.


Subject(s)
Autism Spectrum Disorder/psychology , Autism Spectrum Disorder/therapy , Friends/psychology , Learning/physiology , Social Skills , Translating , Adolescent , Autism Spectrum Disorder/epidemiology , Child , Female , Hong Kong/epidemiology , Humans , Male , Social Adjustment , Surveys and Questionnaires , Treatment Outcome
2.
Paediatr Anaesth ; 27(1): 45-51, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27779344

ABSTRACT

BACKGROUND: Dexmedetomidine is a selective alpha-2 adrenergic agonist with sedative, analgesic, and anxiolytic properties. Dexmedetomidine has not been approved for use in pediatrics. Dexmedetomidine has been reported to depress sinus node and atrioventricular nodal function in pediatric patients; it has been suggested that the use of dexmedetomidine may not be desirable during electrophysiological studies. AIM: We hypothesize that the use of dexmedetomidine does not inhibit the induction of supraventricular tachyarrhythmias (SVT) during electrophysiological studies and does not inhibit the ablation of such arrhythmias. METHODS: In this retrospective, observational cohort study, we reviewed all cases presenting to the cardiac catheterization laboratory for diagnosis or treatment of SVT since 2007. All cases were performed by the same electrophysiologist. The anesthesia was provided by one of the three cardiac anesthesiologists. One cardiac anesthesiologist did not use dexmedetomidine during electrophysiological studies. A second used dexmedetomidine, but only with an infusion. The third used dexmedetomidine with a primary bolus and an infusion. Thus, the patients were stratified into three different groups: Group 1 patients did not receive any dexmedetomidine. Group 2 patients received a dexmedetomidine infusion of 0.5-1 µg·kg-1 ·h-1 . Group 3 patients received a dexmedetomidine infusion of 0.5-1 µg·kg-1 ·h-1 and a dexmedetomidine bolus prior to the infusion of 0.5-1 µg·kg-1 . We then compared those patients for the following variables: demographic data including age, sex, height, weight; anesthetic data such as, mask vs intravenous induction, identity of induction agent, amount of sevoflurane and propofol used; amount of dexmedetomidine used; presence of congenital heart disease and other comorbidities; the need for isoproterenol and dose, the need for adenosine and dose, and the need for any other medications to affect rhythm both before and after radiofrequency ablation; the ability to induce the arrhythmia, the type of arrhythmia, the presence of Wolff-Parkinson-White syndrome, the presence of an accessory pathway, the ablation rate, and the recurrence rate. RESULTS: There was no difference in the anesthetic agents, except there was a lesser amount of propofol used in the dexmedetomidine groups (χ2(2) = 48.2, P < 0.001). There was no difference in the electrophysiological parameters among groups, except the Group 1 patients did require the use of isoproterenol in the preablation period less often compared to the dexmedetomidine groups (χ2(2) = 15.2, P < 0.01). However, with the greater use of isoproterenol, there was no difference in the ability to induce the arrhythmia. Moreover, the percentage of patients ablated, and the recurrence rate among groups was the same. CONCLUSIONS: We conclude that dexmedetomidine does not interfere with the conduct of electrophysiological studies for SVT and the successful ablation of such arrhythmias. However, dexmedetomidine use did result in a greater need for isoproterenol.


Subject(s)
Dexmedetomidine/pharmacology , Electrophysiologic Techniques, Cardiac/statistics & numerical data , Hypnotics and Sedatives/pharmacology , Tachycardia, Supraventricular/diagnosis , Adolescent , Child , Female , Humans , Male , Retrospective Studies
3.
Catheter Cardiovasc Interv ; 72(3): 392-398, 2008 Sep 01.
Article in English | MEDLINE | ID: mdl-18727116

ABSTRACT

OBJECTIVE: The objective of this study is to examine the safety/efficacy of alternative routes of vascular access (ARVA) for successful performance of interventions. BACKGROUND: Complex interventional catheterizations may be required in children with limited vascular access, vascular constraints relative to size, and hemodynamic instability. Our approach has been to utilize ARVA in selected cases. METHODS: ARVA pertains to any vessel excluding femoral, jugular/subclavian veins, or umbilical access. A retrospective review performed on patients with an intervention utilizing ARVA between August 1995 and January 2004 was performed. Patients were divided by clinical status: critically ill/emergent (A), elective cases (B). Procedural success was based on previously published criteria. RESULTS: Sixty-four interventions were performed in 50 patients using 54 ARVA. ARVA utilized: radial (1), axillary (2), brachial (2), carotid arteries (25); brachial (2) hepatic (9) veins; and open chest/direct cardiac puncture (13). ARVA provided successful access to target lesions. Interventions included stents (30), valvuloplasty (16), angioplasty (14), and one each of vascular occlusion, septal occlusion, accessory pathway ablation, and septostomy. Group A patients were smaller (P < 0.0002) and younger (P < 0.004) than B. All open chest/direct cardiac and the majority (71%) of carotid arterial approaches were performed in group A. Fifty-six (88%) inteventions were successful with no difference between groups A (88%) and B (86%). There were two complications. Neither resulted in long-term sequelae. CONCLUSIONS: ARVA may provide a strategic advantage that may be safely applied to a variety of interventions regardless of patient size or degree of illness. These techniques may further extend the scope of successful interventions in children.


Subject(s)
Angioplasty, Balloon, Coronary , Cardiac Catheterization , Cardiac Surgical Procedures , Catheter Ablation , Heart Defects, Congenital/therapy , Adolescent , Angioplasty, Balloon, Coronary/instrumentation , Cardiac Catheterization/adverse effects , Cardiac Catheterization/methods , Cardiac Surgical Procedures/instrumentation , Child , Child, Preschool , Coronary Angiography , Critical Illness , Elective Surgical Procedures , Heart Defects, Congenital/diagnostic imaging , Heart Defects, Congenital/surgery , Humans , Infant , Infant, Newborn , Punctures , Retrospective Studies , Stents , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...